ERBB2 and breast carcinoma: This finding is consistent with a previous study by Polyak and colleagues, which found that patient‐derived primary or CAF cells from breast or brain specimens similarly desensitized HER2‐positive breast cancer cells to the HER2 inhibitor lapatinib (Marusyk et al, 2016).